# CDT Equity Inc.: financial statements, quarterly

CDT · Nasdaq · CIK 1896212 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cdt.md) · [Financials](/companies/cdt/financials.md) · [Filings](/companies/cdt/filings.md) · [Insiders](/companies/cdt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cdt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [0.1](/filings/0001641172-25-024123.md) | [0.0](/filings/0001641172-25-024140.md) | [3.1](/filings/0001493152-25-022373.md) | [0.1 d](/filings/0001493152-26-016858.md) | [0.9](/filings/0001493152-26-033380.md) | [1.9](/filings/0001493152-26-037458.md) | [1.5](/filings/0001493152-25-022373.md) | [0.7 d](/filings/0001493152-26-016858.md) | [0.8](/filings/0001493152-26-033380.md) | [0.3](/filings/0001493152-26-037458.md) |
| Operating income | $m | [(0.4)](/filings/0001493152-24-046088.md) | [(2.4) d](/filings/0001641172-25-001246.md) | [(3.0)](/filings/0001641172-25-024123.md) | [(3.1)](/filings/0001641172-25-024140.md) | [(5.8)](/filings/0001493152-25-022373.md) | [(3.5) d](/filings/0001493152-26-016858.md) | [(3.6)](/filings/0001493152-26-033380.md) | [(5.0)](/filings/0001493152-26-037458.md) | [(7.0)](/filings/0001493152-25-022373.md) | [(21.2) d](/filings/0001493152-26-016858.md) | [(3.7)](/filings/0001493152-26-033380.md) | [(3.0)](/filings/0001493152-26-037458.md) |
| Interest expense | $m | [0.0](/filings/0001493152-24-046088.md) | not reported | [0.1](/filings/0001493152-24-046074.md) | [0.1](/filings/0001493152-24-046080.md) | [0.3](/filings/0001493152-24-046088.md) | [(0.5) d](/filings/0001493152-26-016858.md) | [0.1](/filings/0001641172-25-024123.md) | [0.1](/filings/0001641172-25-024140.md) | [0.1](/filings/0001493152-25-022373.md) | [0.0 d](/filings/0001493152-26-016858.md) | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [2.6](/filings/0001493152-24-046088.md) | [0.2 d](/filings/0001641172-25-001246.md) | [(3.6)](/filings/0001641172-25-024123.md) | [(5.4)](/filings/0001641172-25-024140.md) | [(6.5)](/filings/0001493152-25-022373.md) | [(2.4) d](/filings/0001493152-26-016858.md) | [(4.8)](/filings/0001493152-26-033380.md) | [(6.0)](/filings/0001493152-26-037458.md) | [(7.1)](/filings/0001493152-25-022373.md) | [(21.3) d](/filings/0001493152-26-016858.md) | [(4.1)](/filings/0001493152-26-033380.md) | [(4.6)](/filings/0001493152-26-037458.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001493152-24-046088.md) | not reported | [(4.81)](/filings/0001641172-25-024123.md) | [(109.33)](/filings/0001641172-25-024140.md) | [(889.58)](/filings/0001493152-25-022373.md) | not reported | [(3670.27)](/filings/0001493152-26-033380.md) | [(10940.11)](/filings/0001493152-26-037458.md) | [(13.16)](/filings/0001493152-25-022373.md) | not reported | [(5.56)](/filings/0001493152-26-033380.md) | [(8.71)](/filings/0001493152-26-037458.md) |
| Basic EPS | $ per share | [0.04](/filings/0001493152-24-046088.md) | not reported | [(4.81)](/filings/0001641172-25-024123.md) | [(109.33)](/filings/0001641172-25-024140.md) | [(889.58)](/filings/0001493152-25-022373.md) | not reported | [(3670.27)](/filings/0001493152-26-033380.md) | [(10940.11)](/filings/0001493152-26-037458.md) | [(13.16)](/filings/0001493152-25-022373.md) | not reported | [(5.56)](/filings/0001493152-26-033380.md) | [(8.71)](/filings/0001493152-26-037458.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.6](/filings/0001493152-23-042184.md) | [4.2](/filings/0001641172-25-001246.md) | [1.8](/filings/0001493152-24-046074.md) | [0.2](/filings/0001493152-24-046080.md) | [0.1](/filings/0001493152-24-046088.md) | [0.6](/filings/0001493152-26-016858.md) | [2.1](/filings/0001641172-25-024123.md) | [3.3](/filings/0001641172-25-024140.md) | [3.8](/filings/0001493152-25-022373.md) | [1.5](/filings/0001493152-26-037458.md) | [0.1](/filings/0001493152-26-033380.md) | [0.7](/filings/0001493152-26-037458.md) |
| Current assets | $m | [10.4](/filings/0001493152-23-042184.md) | [5.7](/filings/0001641172-25-001246.md) | [3.2](/filings/0001493152-24-046074.md) | [1.6](/filings/0001493152-24-046080.md) | [1.4](/filings/0001493152-24-046088.md) | [2.7](/filings/0001493152-26-016858.md) | [5.9](/filings/0001641172-25-024123.md) | [6.4](/filings/0001641172-25-024140.md) | [7.1](/filings/0001493152-25-022373.md) | [4.4](/filings/0001493152-26-037458.md) | [3.1](/filings/0001493152-26-033380.md) | [2.9](/filings/0001493152-26-037458.md) |
| Total assets | $m | [12.0](/filings/0001493152-23-042184.md) | [7.2](/filings/0001641172-25-001246.md) | [4.9](/filings/0001493152-24-046074.md) | [3.3](/filings/0001493152-24-046080.md) | [3.0](/filings/0001493152-24-046088.md) | [4.2](/filings/0001493152-26-016858.md) | [7.7](/filings/0001641172-25-024123.md) | [8.0](/filings/0001641172-25-024140.md) | [8.6](/filings/0001493152-25-022373.md) | [5.7](/filings/0001493152-26-037458.md) | [127](/filings/0001493152-26-033380.md) | [127](/filings/0001493152-26-037458.md) |
| Current liabilities | $m | [4.6](/filings/0001493152-23-042184.md) | [1.8](/filings/0001641172-25-001246.md) | [7.7](/filings/0001493152-24-046074.md) | [8.6](/filings/0001493152-24-046080.md) | [12.0](/filings/0001493152-24-046088.md) | [10.7](/filings/0001493152-26-016858.md) | [4.5](/filings/0001641172-25-024123.md) | [4.4](/filings/0001641172-25-024140.md) | [4.3](/filings/0001493152-25-022373.md) | [12.8](/filings/0001493152-26-037458.md) | [21.6](/filings/0001493152-26-033380.md) | [23.4](/filings/0001493152-26-037458.md) |
| Total liabilities | $m | [13.1](/filings/0001493152-23-042184.md) | [7.7](/filings/0001641172-25-001246.md) | [8.0](/filings/0001493152-24-046074.md) | [8.8](/filings/0001493152-24-046080.md) | [12.1](/filings/0001493152-24-046088.md) | [11.0](/filings/0001493152-26-016858.md) | [4.6](/filings/0001641172-25-024123.md) | [4.5](/filings/0001641172-25-024140.md) | [4.3](/filings/0001493152-25-022373.md) | [12.8](/filings/0001493152-26-037458.md) | [21.6](/filings/0001493152-26-033380.md) | [23.6](/filings/0001493152-26-037458.md) |
| Shareholders' equity | $m | [(1.1)](/filings/0001493152-23-042184.md) | [(0.5)](/filings/0001493152-26-016858.md) | [(3.1)](/filings/0001641172-25-024140.md) | [(5.5)](/filings/0001493152-25-022373.md) | [(9.1)](/filings/0001493152-25-022373.md) | [(6.8)](/filings/0001493152-26-037458.md) | [3.1](/filings/0001493152-26-037458.md) | [3.5](/filings/0001493152-26-037458.md) | [4.3](/filings/0001493152-25-022373.md) | [(7.2)](/filings/0001493152-26-037458.md) | [105](/filings/0001493152-26-037458.md) | [103](/filings/0001493152-26-037458.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(524) d](/filings/0001493152-24-046088.md) | [(4,803) d](/filings/0001641172-25-001246.md) | [(2,357)](/filings/0001641172-25-024123.md) | [(1,513) d](/filings/0001641172-25-024140.md) | [(1,999) d](/filings/0001493152-25-022373.md) | [(3,813) d](/filings/0001493152-26-016858.md) | [(3,929)](/filings/0001493152-26-033380.md) | [(2,580) d](/filings/0001493152-26-037458.md) | [(4,410) d](/filings/0001493152-25-022373.md) | [(4,636) d](/filings/0001493152-26-016858.md) | [(1,894)](/filings/0001493152-26-033380.md) | [(544) d](/filings/0001493152-26-037458.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | [41.0 d](/filings/0001493152-24-046088.md) | [0.0 d](/filings/0001641172-25-001246.md) | [404](/filings/0001641172-25-024123.md) | [1.0 d](/filings/0001641172-25-024140.md) | [(7.0) d](/filings/0001493152-25-022373.md) | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.3](/filings/0001493152-23-042184.md) | [64.6](/filings/0001493152-24-046074.md) | [65.8](/filings/0001493152-24-046080.md) | [66.1](/filings/0001493152-24-046088.md) | [0.7](/filings/0001641172-25-024123.md) | [0.0](/filings/0001641172-25-024140.md) | [0.0](/filings/0001493152-25-022373.md) | [0.0](/filings/0001493152-26-033380.md) | [0.0](/filings/0001493152-26-037458.md) | [0.5](/filings/0001493152-25-022373.md) | [0.7](/filings/0001493152-26-033380.md) | [0.5](/filings/0001493152-26-037458.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 786,670 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037458.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.